Inno-Gene Past Earnings Performance
Past criteria checks 0/6
Inno-Gene's earnings have been declining at an average annual rate of -35.1%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 3.7% per year.
Key information
-35.1%
Earnings growth rate
-34.5%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 3.7% |
| Return on equity | -221.4% |
| Net Margin | -1,668.9% |
| Next Earnings Update | 08 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Inno-Gene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -6 | 2 | 0 |
| 31 Mar 24 | 0 | -1 | 2 | 0 |
| 31 Dec 23 | 1 | -6 | 3 | 0 |
| 30 Sep 23 | 2 | -2 | 4 | 0 |
| 30 Jun 23 | 3 | -2 | 6 | 0 |
| 31 Mar 23 | -9 | -6 | -1 | 0 |
| 31 Dec 22 | 16 | 0 | 12 | 0 |
| 30 Sep 22 | 24 | 0 | 15 | 0 |
| 30 Jun 22 | 33 | 3 | 16 | 0 |
| 31 Mar 22 | 39 | 10 | 15 | 0 |
| 31 Dec 21 | 30 | 6 | 12 | 0 |
| 30 Sep 21 | 23 | 6 | 8 | 0 |
| 30 Jun 21 | 15 | 5 | 4 | 0 |
| 31 Mar 21 | 6 | 1 | 2 | 0 |
| 31 Dec 20 | 5 | 0 | 1 | 0 |
| 30 Sep 20 | 3 | 1 | 1 | 0 |
| 30 Jun 20 | 2 | 0 | 1 | 0 |
| 31 Mar 20 | 1 | 0 | 1 | 0 |
| 31 Dec 19 | 1 | 0 | 1 | 0 |
| 30 Sep 19 | 1 | -1 | 1 | 0 |
| 30 Jun 19 | 2 | 1 | 1 | 0 |
| 31 Mar 19 | 3 | 1 | 1 | 0 |
| 31 Dec 18 | 3 | 0 | 2 | 0 |
| 30 Sep 18 | 3 | 1 | 2 | 0 |
| 30 Jun 18 | 3 | 1 | 2 | 0 |
| 31 Mar 18 | 3 | 1 | 2 | 0 |
| 31 Dec 17 | 3 | 1 | 2 | 0 |
| 30 Sep 17 | 4 | 0 | 3 | 0 |
| 30 Jun 17 | 4 | -1 | 3 | 0 |
| 31 Mar 17 | 4 | -2 | 3 | 0 |
| 31 Dec 16 | 5 | -3 | 4 | 0 |
| 30 Sep 16 | 5 | -3 | 5 | 0 |
| 30 Jun 16 | 4 | -3 | 4 | 0 |
| 31 Mar 16 | 5 | -1 | 4 | 0 |
| 31 Dec 15 | 4 | -1 | 4 | 0 |
| 30 Sep 15 | 4 | 1 | 3 | 0 |
| 30 Jun 15 | 4 | 2 | 3 | 0 |
| 31 Mar 15 | 4 | 2 | 2 | 0 |
| 31 Dec 14 | 4 | 2 | 2 | 0 |
| 30 Sep 14 | 4 | 0 | 2 | 0 |
| 30 Jun 14 | 4 | -1 | 2 | 0 |
| 31 Mar 14 | 3 | -1 | 2 | 0 |
| 31 Dec 13 | 3 | 0 | 2 | 0 |
Quality Earnings: WQ3 is currently unprofitable.
Growing Profit Margin: WQ3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: WQ3 is unprofitable, and losses have increased over the past 5 years at a rate of 35.1% per year.
Accelerating Growth: Unable to compare WQ3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WQ3 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.9%).
Return on Equity
High ROE: WQ3 has a negative Return on Equity (-221.37%), as it is currently unprofitable.